Evidence map›Paper›PMID 36722623›Full record

Trial reportDiabetes, obesity & metabolism2023

Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).

Yuka Takahashi, Hiroshi Nomoto, Hiroki Yokoyama, Yoshinari Takano, So Nagai, Atsushi Tsuzuki, Kyu Yong Cho, Aika Miya, Hiraku Kameda, Jun Takeuchi and 6 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06243536 (The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients), which is not on this map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06243536 phase4unknown statusstarted 2024, after this paper: background citation

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

Ran2024Enrolled60Registered outcomes3Posted comparisons0ConditionsDisordered Eating Behaviors, Overweight, Type 2 DiabetesArmssemaglutide, Standard of care
PMID 27208320PMID 25870084PMID 25330463PMID 25745131PMID 24245943PMID 21157325PMID 19336687PMID 17498508PMID 16682865PMID 11728508PMID 26301188PMID 27443001other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. CanInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuka TakahashiDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-0639-3170
Hiroshi NomotoDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0003-0713-221X
Hiroki YokoyamaJiyugaoka Medical Clinic, Obihiro, Japan.
Yoshinari TakanoDepartment of Diabetes and Endocrinology, Tonan Hospital, Sapporo, Japan.
So NagaiDivision of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Center, NTT East Corporation, Sapporo, Japan.
Atsushi TsuzukiDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Kyu Yong ChoDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Aika MiyaDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-3313-6946
Hiraku KamedaDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Jun TakeuchiSapporo Diabetes and Thyroid Clinic, Sapporo, Japan.
Shinji TanedaDiabetes Center, Manda Memorial Hospital, Sapporo, Japan.
Yoshio KuriharaKurihara Clinic, Sapporo, Japan.
Tatsuya AtsumiDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Akinobu NakamuraDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hideaki MiyoshiDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-5909-3243
SWITCH-SEMA 1 study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the effects of switching from liraglutide or dulaglutide to once-weekly semaglutide on glycaemic control and treatment satisfaction in patients with type 2 diabetes. MATERIALS AND

methodsIn this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy. The primary endpoint was the mean change in glycated haemoglobin over 24 weeks. The secondary endpoints included the changes of Diabetes Treatment Satisfaction Questionnaire scores, body weight and metabolic indices.

resultsIn total, 110 patients were enrolled, and 10 were excluded; therefore, 37 patients in plan A and 63 patients in plan B completed the study. Glycated haemoglobin levels were significantly reduced in the semaglutide group in both plans [plan A, 7.8% ± 1.0% to 7.8% ± 0.7% (liraglutide) vs. 7.9% ± 0.7% to 7.3% ± 0.7% (semaglutide), p < .01; plan B, 7.8% ± 1.0% to 7.9% ± 1.2% (dulaglutide) vs. 7.8% ± 0.8% to 7.1% ± 0.6% (semaglutide), p < .01]. Semaglutide also improved Diabetes Treatment Satisfaction Questionnaire scores in both groups (plan A, +0.1 vs. +8.3, p < .01; plan B, -1.2 vs. +3.5, p < .01). Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters.

conclusionsOnce-weekly semaglutide administration improved glycaemic control and treatment satisfaction after switching from liraglutide or dulaglutide. These results highlighted a useful treatment option for patients with metabolic abnormalities despite glucagon-like receptor-1 receptor agonist treatment.

Indexed as

Diabetes Mellitus, Type 2Body WeightGlucagon-Like PeptidesGlycated HemoglobinGlycemic ControlHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutidePatient SatisfactionPersonal SatisfactionProspective StudiesRecombinant Fusion ProteinsSemaglutidedulaglutideGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsSemaglutideclinical trialdulaglutideGLP-1 analogueliraglutidesemaglutidetype 2 diabetes

Identifiers

PMID36722623

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.